MicroPort® Selected as "2017 China Innovative Medical Device Company"

Chongqing, China – On December 17, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort^®") was selected as "2017 China Innovative Medical Device Company" during the 10th China Pharmaceutical Strategy Summit 2017. MicroPort^® Chief Operation Officer Glendy Wang accepted the award on behalf of the company and delivered a report of MicroPort^®'s Innovation Path during the conference. Hosted by China National Pharmaceutical Industry Information Center, China Association of Pharmaceutical Commence, and Chongqing bio-pharmaceutical Industrial Park, the conference focused on the development trend of pharmaceuticals industry, covered topics related with "pharmaceuticals, device, medical service and online medical care" as well as released the list of "Index of Economic Operation of 2017 China Pharmaceuticals Industry" and the list of "2017 China Innovative Medical Device Company".

China Pharmaceutical Strategy Summit is a premier conference in China's pharmaceutical industry, which provides an open platform for domestic healthcare companies to exchange ideas on innovation achievements and innovation management annually. The list of "2017 China Innovative Medical Device Company" is made by China National Pharmaceutical Industry Information Center according to statistics of its database, annual statistical report of China Pharmaceutics and other official data. A total of 10 companies, including MicroPort^®, were included in the list.

Since its establishment in 1998, MicroPort^® has become a leading interventional medical device provider in China. It promotes the development and popularization of interventional treatment as well as the development of interdisciplines such as intelligent manufacturing, biological materials, and 3D printing. With over 200 products currently approved for use in over 5,000 hospitals worldwide, MicroPort^® is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds. MicroPort^® was granted several national science and technology achievements awards and provincial-level honors. In the future, MicroPort^® will continue to strive for innovation, improve product offering and company governance, and focus on creating a sound environment for innovation and an efficient mechanism to cultivate innovative talents, and act as a role model to promote the development of China's high-end medical device industry.